"We have felt for some time that there are pockets of excess capacity in the industry and we'll look to see whether we can help create some value by being part of the consolidation around those."
–Bob Bradway, CEO, Amgen Inc., speaking on the company's fourth-quarter earnings call

"We got more than we expected. We proved that we improved the LVEF [left ventricular ejection fraction] function. We proved that six-minute walk [test results] improve. We proved that the afib burden is way lower; we cut it by more than 50 percent between these two groups. It's very important that the mortality benefit gets into effect in 2.5 to three years after they were ablated, with the initial effect within three to four or six months after the initial treatment. What we know now is that if you ablate people with low systolic ejection fraction, we can save lives, prolong lives and keep people alive in the hospital."
–Nassir Marrouche, professor in internal medicine and executive director of the Comprehensive Arrhythmia Research and Management (CARMA) Center at University of Utah Health and lead author of a study to assess the relative benefits of catheter ablation vs. drug therapy to treat patients with heart failure and atrial fibrillation

"The fundamental problem that we saw here in cataract surgery is that a large portion of the subjects at 24 hours post-surgery had mild to no inflammation," – specifically, 48 percent to 50 percent of participants in the placebo arm, according to top-line data. "Unfortunately, when we designed this study, we actually randomized immediately after surgery and gave the first iontophoretic treatment, which didn't allow exclusion of mild or noninflamed eyes. We see that was a big mistake."
–Stephen From, president and CEO, Eyegate Pharmaceuticals Inc., commenting on disappointing top-line results from a phase IIb study of combination drug/device candidate EGP-437 to treat pain and inflammation in patients following cataract surgery